ATRIAL FIBRILLATION IN HEMATO-ONCOLOGIC PATIENTS: EPIDEMIOLOGY, MECHANISMS, AND CLINICAL IMPLICATIONS
Abstract
Background: Atrial fibrillation (AF) is a common cardiac arrhythmia that affects approximately 2% of the population. In the population of patients with hematological neoplasms, there is an increased risk of developing atrial fibrillation. Despite growing evidence linking AF with hematological malignancies, current research rarely differentiates individual malignancies, leaving significant gaps in understanding disease-specific mechanisms.
Objective: The aim of this study is to demonstrate the correlation between an increased risk of atrial fibrillation in hemato-oncological patients, to present the mechanisms underlying the onset of AF in these patients, and to outline the challenges associated with arrhythmia management in this group of patients
Materials and Methods: The article is based on scientific literature sourced from PubMed, SpringerLink and Google Scholar.
Results: Patients with hematological malignancies have a markedly increased risk of developing atrial fibrillation compared to cancer-free patients. Multiple factors may explain this linking; for example, anemia, electrolyte disruption, cytokine-mediated atrial remodeling, radiation exposure, and side effects of various therapies, including anthracyclines, CAR-T, or tyrosine kinase-inhibitors. AF in this population is often complicated by higher rates of bleeding, thromboembolic events, and treatment interactions.
Conclusions: Atrial fibrillation represents a growing clinical challenge in hematology and oncology, requiring individualized treatment and close multidisciplinary collaboration, especially between cardiologists and oncologists. Current data suggest the need for disease-specific testing, improved risk stratification models, and the identification of predictive biomarkers. A more profound understanding of the mechanisms linking AF and hematologic malignancies could ultimately improve prevention, diagnosis, and tailored therapeutic strategies.
References
Tan, S. C. W., Tang, M. L., Chu, H., Zhao, Y. T., & Weng, C. (2024). Trends in Global Burden and Socioeconomic Profiles of Atrial Fibrillation and Atrial Flutter: Insights from the Global Burden of Disease Study 2021. CJC open, 7(3), 247–258. https://doi.org/10.1016/j.cjco.2024.11.017
Davis, R. C., Hobbs, F. D., Kenkre, J. E., Roalfe, A. K., Iles, R., Lip, G. Y., & Davies, M. K. (2012). Prevalence of atrial fibrillation in the general population and in high-risk groups: the ECHOES study. Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 14(11), 1553–1559. https://doi.org/10.1093/europace/eus087
Staerk, L., Sherer, J. A., Ko, D., Benjamin, E. J., & Helm, R. H. (2017). Atrial Fibrillation: Epidemiology, Pathophysiology, and Clinical Outcomes. Circulation research, 120(9), 1501–1517. https://doi.org/10.1161/CIRCRESAHA.117.309732
Mathur, P., Paydak, H., Thanendrarajan, S., & van Rhee, F. (2016). Atrial Fibrillation in Hematologic Malignancies, Especially After Autologous Hematopoietic Stem Cell Transplantation: Review of Risk Factors, Current Management, and Future Directions. Clinical lymphoma, myeloma & leukemia, 16(2), 70–75. https://doi.org/10.1016/j.clml.2015.10.001
Krok-Schoen, J. L., Fisher, J. L., Stephens, J. A., Mims, A., Ayyappan, S., Woyach, J. A., & Rosko, A. E. (2018). Incidence and survival of hematological cancers among adults ages ≥75 years. Cancer medicine, 7(7), 3425–3433. https://doi.org/10.1002/cam4.1461
Ay, C., Grilz, E., Nopp, S., Moik, F., Königsbrügge, O., Klimek, P., Thurner, S., Posch, F., & Pabinger, I. (2022). Atrial fibrillation and cancer: prevalence and relative risk from a nationwide study. Research and practice in thrombosis and haemostasis, 7(1), 100026. https://doi.org/10.1016/j.rpth.2022.100026
Davis, N. E., Prasitlumkum, N., & Tan, N. Y. (2024). Atrial Fibrillation and Cancer-Epidemiology, Mechanisms, and Management. Journal of clinical medicine, 13(24), 7753. https://doi.org/10.3390/jcm13247753
P.S Yang, M Shim, S.H Kang, S.H Kim, W.J Kim, J.Y Moon, J.H Sung, I.J Kim, S.W Lim, D.H Cha, G.Y.H Lip, B Joung, Incidence of atrial fibrillation in cancer patients according to cancer type, European Heart Journal, Volume 41, Issue Supplement_2, November 2020, ehaa946.3271, https://doi.org/10.1093/ehjci/ehaa946.3271
Yun, J. P., Choi, E. K., Han, K. D., Park, S. H., Jung, J. H., Park, S. H., Ahn, H. J., Lim, J. H., Lee, S. R., & Oh, S. (2021). Risk of Atrial Fibrillation According to Cancer Type: A Nationwide Population-Based Study. JACC. CardioOncology, 3(2), 221–232. https://doi.org/10.1016/j.jaccao.2021.03.006
Littlewood, T., & Mandelli, F. (2002). The effects of anemia in hematologic malignancies: more than a symptom. Seminars in oncology, 29(3 Suppl 8), 40–44. https://doi.org/10.1053/sonc.2002.33532
Lim, W. H., Choi, E. K., Han, K. D., Lee, S. R., Cha, M. J., & Oh, S. (2020). Impact of Hemoglobin Levels and Their Dynamic Changes on the Risk of Atrial Fibrillation: A Nationwide Population-Based Study. Scientific reports, 10(1), 6762. https://doi.org/10.1038/s41598-020-63878-9
Weaver, A., Rubinstein, S., & Cornell, R. F. (2020). Hyperviscosity Syndrome in Paraprotein Secreting Conditions Including Waldenstrom Macroglobulinemia. Frontiers in oncology, 10, 815. https://doi.org/10.3389/fonc.2020.00815
Cecchi, E., Marcucci, R., Poli, D., Antonucci, E., Abbate, R., Gensini, G. F., Prisco, D., & Mannini, L. (2006). Hyperviscosity as a possible risk factor for cerebral ischemic complications in atrial fibrillation patients. The American journal of cardiology, 97(12), 1745–1748. https://doi.org/10.1016/j.amjcard.2006.01.034
Oyajobi B. O. (2007). Multiple myeloma/hypercalcemia. Arthritis research & therapy, 9 Suppl 1(Suppl 1), S4. https://doi.org/10.1186/ar2168
Zhai, S., Zhao, Q., Wang, J., Li, L., Chen, J., & Zhang, Z. (2025). A Characteristic Electrocardiographic Manifestation Suggests Hypercalcemia. Diagnostics, 15(23), 3034. https://doi.org/10.3390/diagnostics15233034
O'Regan, S., Carson, S., Chesney, R. W., & Drummond, K. N. (1977). Electrolyte and acid-base disturbances in the management of leukemia. Blood, 49(3), 345–353.
Rafaqat, S., Rafaqat, S., Khurshid, H. et al. Electrolyte’s imbalance role in atrial fibrillation: Pharmacological management. Int J Arrhythm 23, 15 (2022). https://doi.org/10.1186/s42444-022-00065-z
Tseng, Y. D., & Ng, A. K. (2020). Hematologic Malignancies. Hematology/oncology clinics of North America, 34(1), 127–142. https://doi.org/10.1016/j.hoc.2019.08.020
Kim, K. H., Oh, J., Yang, G., Lee, J., Kim, J., Gwak, S. Y., Cho, I., Lee, S. H., Byun, H. K., Choi, H. K., Kim, J., Chang, J. S., Kang, S. M., & Yoon, H. I. (2022). Association of Sinoatrial Node Radiation Dose With Atrial Fibrillation and Mortality in Patients With Lung Cancer. JAMA oncology, 8(11), 1624–1634. https://doi.org/10.1001/jamaoncol.2022.4202
Korantzopoulos, P., Letsas, K. P., Tse, G., Fragakis, N., Goudis, C. A., & Liu, T. (2018). Inflammation and atrial fibrillation: A comprehensive review. Journal of arrhythmia, 34(4), 394–401. https://doi.org/10.1002/joa3.12077
Hirano T. (2021). IL-6 in inflammation, autoimmunity and cancer. International immunology, 33(3), 127–148. https://doi.org/10.1093/intimm/dxaa078
Burger R. (2013). Impact of interleukin-6 in hematological malignancies. Transfusion medicine and hemotherapy: offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie, 40(5), 336–343. https://doi.org/10.1159/000354194
Ihara, K., & Sasano, T. (2022). Role of Inflammation in the Pathogenesis of Atrial Fibrillation. Frontiers in physiology, 13, 862164. https://doi.org/10.3389/fphys.2022.862164
Zhang, X., Zhu, L., Zhang, H., Chen, S., & Xiao, Y. (2022). CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges. Frontiers in immunology, 13, 927153. https://doi.org/10.3389/fimmu.2022.927153
Sadelain, M., Brentjens, R., & Rivière, I. (2013). The basic principles of chimeric antigen receptor design. Cancer discovery, 3(4), 388–398. https://doi.org/10.1158/2159-8290.CD-12-0548
Yu, S., Li, A., Liu, Q., Li, T., Yuan, X., Han, X., & Wu, K. (2017). Chimeric antigen receptor T cells: a novel therapy for solid tumors. Journal of hematology & oncology, 10(1), 78. https://doi.org/10.1186/s13045-017-0444-9
Simbaqueba, C. C., Aponte, M. P., Kim, P., Deswal, A., Palaskas, N. L., Iliescu, C., Jahangir, E., Yang, E. H., Steiner, R. E., & Lopez-Mattei, J. (2020). Cardiovascular Complications of Chimeric Antigen Receptor T-Cell Therapy: The Cytokine Release Syndrome and Associated Arrhythmias. Journal of immunotherapy and precision oncology, 3(3), 113–120. https://doi.org/10.36401/JIPO-20-10
Peci, F., Dekker, L., Pagliaro, A., van Boxtel, R., Nierkens, S., & Belderbos, M. (2022). The cellular composition and function of the bone marrow niche after allogeneic hematopoietic cell transplantation. Bone marrow transplantation, 57(9), 1357–1364. https://doi.org/10.1038/s41409-022-01728-0
Almeida, S. O., Skelton, R. J., Adigopula, S., & Ardehali, R. (2015). Arrhythmia in stem cell transplantation. Cardiac electrophysiology clinics, 7(2), 357–370. https://doi.org/10.1016/j.ccep.2015.03.012
Chang, E. K., Chanson, D., Teh, J. B., Iukuridze, A., Peng, K., Forman, S. J., Nakamura, R., Wong, F. L., Cai, L., & Armenian, S. H. (2021). Atrial Fibrillation in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 39(8), 902–910. https://doi.org/10.1200/JCO.20.02401
Teuffel, O., Leibundgut, K., Lehrnbecher, T., Alonzo, T. A., Beyene, J., & Sung, L. (2013). Anthracyclines during induction therapy in acute myeloid leukaemia: a systematic review and meta-analysis. British journal of haematology, 161(2), 192–203. https://doi.org/10.1111/bjh.12233
Volkova, M., & Russell, R., 3rd (2011). Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment. Current cardiology reviews, 7(4), 214–220. https://doi.org/10.2174/157340311799960645
Ran, T., Chen, J., She, Q., Mu, Y., Zhang, M., Mao, M., Zuo, Z., & Li, J. (2024). Anthracycline-induced arrhythmias in breast cancer therapy: A meta-analysis of single-arm trials. PloS one, 19(5), e0303208. https://doi.org/10.1371/journal.pone.0303208
Ilkhanoff, L., Atwater, B., & Barac, A. (2024). Atrial Fibrillation Amplifies Heart Failure Risk in Anthracycline Treated Cancer Patients: Stacking Risk Factors in the Vulnerable. The American journal of cardiology, 218, 121–122. https://doi.org/10.1016/j.amjcard.2024.02.017
Xiao, L., Salem, J. E., Clauss, S., Hanley, A., Bapat, A., Hulsmans, M., Iwamoto, Y., Wojtkiewicz, G., Cetinbas, M., Schloss, M. J., Tedeschi, J., Lebrun-Vignes, B., Lundby, A., Sadreyev, R. I., Moslehi, J., Nahrendorf, M., Ellinor, P. T., & Milan, D. J. (2020). Ibrutinib-Mediated Atrial Fibrillation Attributable to Inhibition of C-Terminal Src Kinase. Circulation, 142(25), 2443–2455. https://doi.org/10.1161/CIRCULATIONAHA.120.049210
Teng, G., Shang, K., Zhang, Y., Duan, Y., Du, C., Wang, Y., Li, Y., Zhang, H., Peng, L., Wei, X., Tse, G., Zhou, Y., Lip, G. Y. H., Liu, T., Yang, W., Duan, M. & Bai, J. (2025). Incidence, Outcomes and Risk Factors for Atrial Fibrillation in Patients With JAK2 V617F‑Positive Myeloproliferative Neoplasms. Cancer Medicine, 14(13), Article e71015. https://doi.org/10.1002/cam4.71015
Siontis, K. C., Gersh, B. J., Killian, J. M., Noseworthy, P. A., McCabe, P., Weston, S. A., Roger, V. L., & Chamberlain, A. M. (2016). Typical, atypical, and asymptomatic presentations of new-onset atrial fibrillation in the community: Characteristics and prognostic implications. Heart rhythm, 13(7), 1418–1424. https://doi.org/10.1016/j.hrthm.2016.03.003
Bin Salih, S. A., Showlag, M. S., Al-Qahtani, M. A., Taha, A., Yousuf, M., & Abdullah, M. (2011). Clinical characteristics of patients with atrial fibrillation at a tertiary care hospital in the central region of Saudi Arabia. Journal of family & community medicine, 18(2), 80–84. https://doi.org/10.4103/2230-8229.83374
Lacoste, J.L., Szymanski, T.W., Avalon, J.C. et al. Atrial Fibrillation Management: A Comprehensive Review with a Focus on Pharmacotherapy, Rate, and Rhythm Control Strategies. Am J Cardiovasc Drugs 22, 475–496 (2022). https://doi.org/10.1007/s40256-022-00529-6
Asnani, A., Manning, A., Mansour, M., Ruskin, J., Hochberg, E. P., & Ptaszek, L. M. (2017). Management of atrial fibrillation in patients taking targeted cancer therapies. Cardio-oncology (London, England), 3, 2. https://doi.org/10.1186/s40959-017-0021-y
Rose, A. J., Sharman, J. P., Ozonoff, A., Henault, L. E., & Hylek, E. M. (2007). Effectiveness of warfarin among patients with cancer. Journal of general internal medicine, 22(7), 997–1002. https://doi.org/10.1007/s11606-007-0228-y
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., Wang, S., Alings, M., Xavier, D., Zhu, J., Diaz, R., Lewis, B. S., Darius, H., Diener, H. C., Joyner, C. D., Wallentin, L., … RE-LY Steering Committee and Investigators (2009). Dabigatran versus warfarin in patients with atrial fibrillation. The New England journal of medicine, 361(12), 1139–1151. https://doi.org/10.1056/NEJMoa0905561
Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., Breithardt, G., Halperin, J. L., Hankey, G. J., Piccini, J. P., Becker, R. C., Nessel, C. C., Paolini, J. F., Berkowitz, S. D., Fox, K. A., Califf, R. M., & ROCKET AF Investigators (2011). Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. The New England journal of medicine, 365(10), 883–891. https://doi.org/10.1056/NEJMoa1009638
Granger, C. B., Alexander, J. H., McMurray, J. J., Lopes, R. D., Hylek, E. M., Hanna, M., Al-Khalidi, H. R., Ansell, J., Atar, D., Avezum, A., Bahit, M. C., Diaz, R., Easton, J. D., Ezekowitz, J. A., Flaker, G., Garcia, D., Geraldes, M., Gersh, B. J., Golitsyn, S., Goto, S., … ARISTOTLE Committees and Investigators (2011). Apixaban versus warfarin in patients with atrial fibrillation. The New England journal of medicine, 365(11), 981–992. https://doi.org/10.1056/NEJMoa1107039
Giugliano, R. P., Ruff, C. T., Braunwald, E., Murphy, S. A., Wiviott, S. D., Halperin, J. L., Waldo, A. L., Ezekowitz, M. D., Weitz, J. I., Špinar, J., Ruzyllo, W., Ruda, M., Koretsune, Y., Betcher, J., Shi, M., Grip, L. T., Patel, S. P., Patel, I., Hanyok, J. J., Mercuri, M., … ENGAGE AF-TIMI 48 Investigators (2013). Edoxaban versus warfarin in patients with atrial fibrillation. The New England journal of medicine, 369(22), 2093–2104. https://doi.org/10.1056/NEJMoa1310907
Zweiker, D., Bergler-Klein, J., Fiedler, L., Toth, G. G., Achleitner, R., Schratter, A., Stix, G., Gabriel, H., Binder, R. K., Rammer, M., Pfeffer, M., Vock, P., Lileg, B., Steinwender, C., Sihorsch, K., Hintringer, F., Adukauskaite, A., Martinek, M., Sturmberger, T., ... Scherr, D. (2024). Left Atrial Appendage Closure in Atrial Fibrillation Patients with Cancer. Journal of Clinical Medicine, 13(21), 6514. https://doi.org/10.3390/jcm13216514
Tandar, A., Nielsen, J., & Whisenant, B. K. (2021). Left Atrial Appendage Closure Review: Addressing Unmet Needs of AF Mediated Stroke Prevention with Evolving Science. Structural Heart, 5(1), 3–10. https://doi.org/10.1080/24748706.2020.1834173
Zhang, Y., Yang, Z., Almani, M.U. et al. Utilization and short-term outcomes of percutaneous left atrial appendage occlusion in patients with cancer. Cardio-Oncology 9, 39 (2023). https://doi.org/10.1186/s40959-023-00192-z
de Carvalho, A. A., de Carvalho, W. A., Donato, G., de Lira Sobral, R. F., Mariz, P. F., Macedo, A. V. S., Melo, M., & Lopes, R. D. (2025). Catheter ablation in patients with atrial fibrillation and cancer: a systematic review and updated meta-analysis. Journal of interventional cardiac electrophysiology: an international journal of arrhythmias and pacing, 10.1007/s10840-025-02176-8. Advance online publication. https://doi.org/10.1007/s10840-025-02176-8
Stephens, D. M., & Byrd, J. C. (2019). How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia. Blood, 133(12), 1298–1307. https://doi.org/10.1182/blood-2018-11-846808
Ganatra, S., Sharma, A., Shah, S., Chaudhry, G. M., Martin, D. T., Neilan, T. G., Mahmood, S. S., Barac, A., Groarke, J. D., Hayek, S. S., Dani, S., Venesy, D., Patten, R., & Nohria, A. (2018). Ibrutinib-Associated Atrial Fibrillation. JACC. Clinical electrophysiology, 4(12), 1491–1500. https://doi.org/10.1016/j.jacep.2018.06.004
Stauder, R., Augschoell, J., Hamaker, M. E., & Koinig, K. A. (2020). Malnutrition in Older Patients With Hematological Malignancies at Initial Diagnosis - Association With Impairments in Health Status, Systemic Inflammation and Adverse Outcome. HemaSphere, 4(1), e332. https://doi.org/10.1097/HS9.0000000000000332
Verrest, L., Wilthagen, E. A., Beijnen, J. H., Huitema, A. D. R., & Dorlo, T. P. C. (2021). Influence of Malnutrition on the Pharmacokinetics of Drugs Used in the Treatment of Poverty-Related Diseases: A Systematic Review. Clinical pharmacokinetics, 60(9), 1149–1169. https://doi.org/10.1007/s40262-021-01031-z
Ibrahim, M. A., & Tivakaran, V. S. (2025). Dofetilide. In StatPearls. StatPearls Publishing.
Li, S., Yu, K., Chen, Y., Luo, W., Zheng, Y., Yang, Y., Yang, X., Wang, X., Gao, X., Wang, X., & Wu, B. (2020). Fatal renal diseases among patients with hematological malignancies: A population-based study. EJHaem, 1(2), 473–480. https://doi.org/10.1002/jha2.99
Copyright (c) 2025 Jakub Tarczykowski, Szymon Stupnicki, Michał Woźniak, Natalia Kwaśniewska, Mikołaj Zakryś, Katarzyna Anna Zakryś, Mateusz Szot, Aleksandra Oparcik
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
